Of important clinical significance, in a review of patients with core binding factor AML, which traditionally confers a more favorable risk stratification, those with concurrent mesothelin expression had a statistically significant higher risk of relapse and worse disease-free survival [121]. This evidence concerns the gene MSLN and acute myeloid leukemia.